Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Real Estate
  • Information Technology
  • Business
Washingtoner

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
Washingtoner/10287890

Trending...
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 113
  • Tacoma: OMWBE Active Certification Class on November 16
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - Washingtoner -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on Washingtoner
  • Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
  • Spokane: SPD Makes an Arrest in Yesterday's Early Morning Shooting
  • Spokane: Mayor Brown Introduces 2027-2028 Budget Proposal
  • Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
  • IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Community Days at Spokane City Council Celebrating Veteran's Day
  • Dr. Latorial Faison Appointed Poet Laureate of Virginia
  • Sparta Services Named to CRN's 2026 AI Innovators List
  • AdLeverage Brings Golf Simulator Contest and Home Services Marketing Expertise to Service World Expo 2026
  • Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
  • TradeJARnal Launches Innovative Trading Journal to Help Stock and Options Traders Build Discipline and Smarter Trading Habits
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • HiLine Homes' "Building Homes & Filling Plates" Food Drive Returns to Support Local Families
  • Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • Miami Dade College and World Affairs Council of Miami announce Navarro-Cabrera scholarship
  • RPP to host first Professional Padel Week in Miami and announce the 2026 USA Awards winners
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
  • International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • AI Needs Guardrails Now: A New Movement Asks People Everywhere to Take the Pledge
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: City and Permittable Partner to Support Rebuilding After Wildfires - 274
  • Spokane: City to provide asbestos testing, host community resource meetings - 226
  • Tacoma: In-Person Workshop on October 22 for Local Businesses on the City’s Revolving Loan Fund Process - 189
  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 149
  • Final Week to Register for Free Spokane Community Conference - 127
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 126
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 113
  • Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 104
  • Holiday Gambling Spending Expected to Rise 12% in December - 101
  • Spokane Police Respond to Fatal Stabbing in Northeast Spokane

Similar on Washingtoner

  • KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
  • Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
  • Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
  • AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute